Checked Nov 8, 2026Start a new check

What was checked

FDA confirms gene therapy DNA integrated into human genomes, inducing cancer. This uses the same DNA-delivery technology as J&J and AstraZeneca COVID shots, so vaccine recipients are potentially at risk for future cancer

Assessment summary

Inaccurate

Zolgensma uses an adeno-associated virus (AAV) vector, while FDA guidance separately identifies adenovirus vectors as having no propensity to integrate. The claim incorrectly treats these distinct vector technologies as the same. The cited FDA evidence does not show that Johnson & Johnson or AstraZeneca COVID-19 vaccines cause cancer through DNA integration. A general theoretical possibility for DNA integration in some gene-therapy contexts cannot substantiate a vaccine-specific cancer warning.

Key findings

Model assessments

Assessment summary

  • The claim misrepresents a specific gene-therapy safety investigation as applying to COVID-19 vaccines.
  • FDA guidance distinguishes adenovirus vectors, which do not have a propensity to integrate, from integrating vectors; it does not establish that Johnson & Johnson or AstraZeneca vaccine recipients face a future cancer risk from genomic integration.fda.gov govinfo.gov

Claims reviewed

This uses the same DNA-delivery technology as J&J and AstraZeneca COVID shots.

Contradicted
Zolgensma uses an adeno-associated virus (AAV) vector, while FDA guidance separately identifies adenovirus vectors as having no propensity to integrate. The claim incorrectly treats these distinct vector technologies as the same.fda.gov fda.gov

This claim may mislead readers without added context.

FDA confirms gene therapy DNA integrated into human genomes, inducing cancer.

Needs context
FDA materials describe a potential risk that DNA integration could contribute to cancer, but the cited FDA investigation concerns Zolgensma, an AAV gene therapy, and does not establish that gene therapy DNA generally induces cancer.fda.gov fda.gov

This claim may mislead readers without added context.

Vaccine recipients are potentially at risk for future cancer.

Needs context
The cited FDA evidence does not show that Johnson & Johnson or AstraZeneca COVID-19 vaccines cause cancer through DNA integration. A general theoretical possibility for DNA integration in some gene-therapy contexts cannot substantiate a vaccine-specific cancer warning.fda.gov govinfo.gov

This claim may mislead readers without added context.

Assessment summary

  • The claim conflates two fundamentally different viral vector technologies.
  • While the FDA did confirm DNA integration and cancer risk with AAV-based gene therapy (Zolgensma), COVID vaccines from J&J and AstraZeneca use adenovirus vectors that lack integration capability.
  • The claim's core conclusion—that vaccine recipients face cancer risk from DNA integration—is not supported by the science.

Claims reviewed

Vaccine recipients are potentially at risk for future cancer

Contradicted
Adenovirus vectors used in COVID vaccines lack the enzymatic machinery for genome integration and are classified by the FDA as non-integrating vectors. The cancer risk identified with Zolgensma does not apply to adenovirus-based vaccines.

This claim may mislead readers without added context.

This uses the same DNA-delivery technology as J&J and AstraZeneca COVID shots

Contradicted
Zolgensma uses adeno-associated virus (AAV) vectors, while J&J uses adenovirus type 26 and AstraZeneca uses chimpanzee adenovirus. These are fundamentally different vector types with different integration properties.

This claim may mislead readers without added context.

FDA confirms gene therapy DNA integrated into human genomes, inducing cancer

Supported
The FDA did confirm in November 2026 that Zolgensma (an AAV-based gene therapy) caused insertional oncogenesis with DNA integration linked to cancer in patients.

Assessment summary

  • The first sentence is supported by a recent FDA statement confirming AAV gene‑therapy DNA integration linked to malignancies in Zolgensma patients fda.gov.
  • The second and third sentences overstate and conflate different technologies and risks: COVID-19 viral‑vector vaccines use different (adenoviral) vectors that are not the same as AAV, and public health authorities report no evidence that those vaccines cause integration‑driven cancer covid19community.nih.gov asgct.org.

Claims reviewed

This uses the same DNA‑delivery technology as J&J and AstraZeneca COVID shots

Needs context
All three use viral vectors to deliver DNA, but Zolgensma uses adeno‑associated virus (AAV) while J&J and AstraZeneca vaccines use non‑replicating adenoviral vectors, which are different families and have different integration properties and safety profiles fda.gov covid19community.nih.gov.

This claim may mislead readers without added context.

so vaccine recipients are potentially at risk for future cancer

Needs context
There is no evidence that adenoviral COVID‑19 vaccines cause integration‑driven cancer; public health sources state the viral vectors used do not integrate into the genome and no signal of vaccine‑caused cancers has been identified covid19community.nih.gov asgct.org.

This claim may mislead readers without added context.

FDA confirms gene therapy DNA integrated into human genomes, inducing cancer.

Supported
The FDA posted that postmarketing reports for the AAV‑based gene therapy onasemnogene abeparvovec (Zolgensma) included confirmed cases where vector DNA integrated near the GLI1 oncogene and were associated with malignancy fda.gov.

Sources cited

15 sources

Share this result